Sun Pharmaceutical Industries Limited has officially addressed recent media reports concerning a potential $12 billion deal involving Organon. Following a nearly 4% dip in stock price, the company clarified that these reports are speculative in nature. Sun Pharma confirmed that there is currently no material event or information that requires disclosure, maintaining its commitment to transparency and governance standards while informing shareholders that the rumors are unfounded.
Clarification on Market Reports
On April 10, 2026, Sun Pharmaceutical Industries Limited issued a formal clarification in response to a news article published by Moneycontrol. The report, titled “Sun Pharma slips nearly 4% after $12 billion Organon deal enters final stage,” had caused significant movement in the company’s share price during the trading session.
Company Stance on Speculation
Sun Pharma explicitly stated that the information circulating in the media is speculative. The company emphasized that there are currently no ongoing negotiations or material developments regarding such a transaction that would necessitate a mandatory disclosure under current market rules. By issuing this statement, the management aims to curb market rumors and ensure that investors rely on verified information.
Commitment to Transparency
The company reiterated its adherence to the highest standards of governance. Sun Pharma reaffirmed that it remains dedicated to keeping stock exchanges and the investing public informed of any material events as they occur, ensuring full compliance and clarity for its stakeholders moving forward.
Source: BSE
